Tier 3 — preclinical

Alpha-ketoglutarate ameliorates age-related osteoporosis via regulating histone methylations

Wang Y, Deng P, Liu Y, Wu Y, Chen Y, Guo Y, Zhang S, Zheng X, Zhou L, Liu W, Li Q, Lin W, Qi X, Ou G, Wang C, Yuan Q
Nature Communications 2020 11(1):5596

Bibliography

PubMed
PMID 33154378
PubMed Central
PMC7645772
DOI
10.1038/s41467-020-19360-1
Funding
National Natural Science Foundation of China, State Key Laboratory of Oral Diseases, and China's National Key R&D Program.
Competing interests
The authors declared no competing interests.

Study snapshot

DesignPreclinical rodent and bone-marrow mesenchymal stem-cell study.
ModelAged mice and rodents plus bone-marrow mesenchymal stromal/stem cells.
SampleMultiple in vivo and cell-culture cohorts; group size varied by experiment.
InterventionExogenous alpha-ketoglutarate administered in aged rodent models, with mechanistic cell experiments.
DurationStudy-specific rodent treatment and bone-regeneration time courses.
EndpointsBone mass and microarchitecture; Bone regeneration; MSC senescence; Histone methylation; BMP signaling; Osteogenic potential

What the study showed, in plain terms

This Nature Communications study examined why bone-forming capacity declines with age and whether alpha-ketoglutarate could modify that biology.

In aged rodents, AKG increased bone mass, reduced age-related bone loss and improved bone regeneration. In aged bone-marrow MSCs, AKG reduced senescence-associated features and improved osteogenic function.

The mechanism involved lower H3K9me3 and H3K27me3 repressive histone marks with increased BMP signaling and Nanog expression. It is strong preclinical bone evidence, not proof that an oral Ca-AKG supplement prevents osteoporosis in people.

Key findings

  • AKG increased bone mass and attenuated age-related bone loss in aged rodent models.
  • AKG improved regenerative and osteogenic behavior of aged bone-marrow MSCs.
  • Epigenetic effects included reductions in H3K9me3 and H3K27me3 with downstream BMP/Nanog signaling changes.

What this study can and cannot tell us

  • Animal and cell evidence only; no oral human Ca-AKG arm.
  • Rodent dosing and exposure cannot be directly converted into a commercial supplement dose.
  • Bone-density or fracture benefits in humans remain unproven.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology